DATA GRAPHICS | Data Byte
Rocket gene therapy among at least 7 PDUFA dates at FDA in March
Expected decisions include gene therapy for LAD-I
March 4, 2026 1:51 AM UTC
March’s PDUFA dates include a resubmission of a lentiviral gene therapy to treat leukocyte adhesion deficiency-I.
Rocket Pharmaceutical Inc. (NASDAQ:RCKT) said the June 2024 complete response letter requested CMC data but that review was by a different CBER than the one reviewing Kresladi marnetegragene autotemcel in 2026...